| The effect of tenidap on the anti-hypertensive efficacy of ACE inhibitors in patients treated for mild to moderate hypertension. | |
| | |
MedLine Citation:
|
PMID: 7547097 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
1. A randomised, placebo controlled, double-blind, parallel group study was conducted to assess the effect of tenidap sodium, a novel cytokine modulating drug, on the stable hypotensive response to the angiotension converting enzyme (ACE) inhibitor enalapril in subjects with mild to moderate, uncomplicated, essential hypertension. 2. Twenty-four male and female hypertensives, aged 33-77 years, received either 120 mg tenidap sodium or matched placebo daily for 22 days concomitantly with enalapril. 3. Mean endpoint supine and standing, systolic and diastolic pressures remained within 10% of baseline in each treatment group. However, the endpoint values were marginally above baseline during double-blind treatment with tenidap and marginally below baseline in the group receiving placebo. The increases in supine and standing systolic pressures in the tenidap group differed significantly from the changes in the placebo group. There were no significant differences between groups in changes in pulse rate. 4. Gastrointestinal side effects of mild to moderate severity attributed to treatment with tenidap were experienced by five subjects, one of whom was withdrawn during the third week of treatment. One subject receiving placebo was withdrawn because of a moderate headache attributed to study treatment. 5. The results of this study suggest that treatment with tenidap may interfere with the anti-hypertensive efficacy of ACE inhibitors. It is recommended that blood pressure should be monitored when tenidap is administered concomitantly with an ACE inhibitor. |
| | |
Authors:
|
W G Rapeport; V C Grimwood; J Hosie; P M Sloan; K Korlipara; B D Silvert; I James; G L Mechie; J L Anderton |
Related Documents
:
|
3532697 - Central haemodynamics in acute myocardial infarction. natural history, relation to enzy... 1996187 - Trial of slow release diltiazem for essential hypertension in general practice. 2120987 - Rapid bolus injection of gadopentetate dimeglumine: absence of side effects in normal v... 9475697 - Efficacy of amlodipine in pediatric bone marrow transplant patients. 7362717 - Relation between isovolumic relaxation period of left ventricle and pulmonary artery pr... 18499547 - Effect of vascular augmentation on the haemodynamics and survival area in a rat abdomin... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: British journal of clinical pharmacology Volume: 39 Suppl 1 ISSN: 0306-5251 ISO Abbreviation: Br J Clin Pharmacol Publication Date: 1995 |
Date Detail:
|
Created Date: 1995-10-26 Completed Date: 1995-10-26 Revised Date: 2009-11-18 |
Medline Journal Info:
|
Nlm Unique ID: 7503323 Medline TA: Br J Clin Pharmacol Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 57S-61S Citation Subset: IM |
Affiliation:
|
Early Clinical Research Group, Pfizer Central Research, Sandwich, Kent, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Analysis of Variance Angiotensin-Converting Enzyme Inhibitors / adverse effects, therapeutic use* Anti-Inflammatory Agents, Non-Steroidal / adverse effects, pharmacology* Double-Blind Method Drug Interactions Enalapril / pharmacology, therapeutic use Female Humans Hypertension / drug therapy* Indoles / adverse effects, pharmacology* Male Middle Aged Time Factors |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin-Converting Enzyme Inhibitors; 0/Anti-Inflammatory Agents, Non-Steroidal; 0/Indoles; 120210-48-2/tenidap; 75847-73-3/Enalapril |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The effect of tenidap on the anti-hypertensive efficacy of thiazide diuretics in patients treated fo...
Next Document: Lack of photosensitising potential of tenidap, a novel anti-rheumatic agent.